App-Quantinova.ai

Mapping global cancer research and control in areas of low and middle income: The need for shared data on a single, interactive platform.

Ali Chisti - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Health care utilization trends in ductal carcinoma in situ admissions.

Nishi Shah - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cancer epidemiology in Connecticut prisons.

Debasmita Saha - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prospective study of the financial burden of cancer clinical trial patients referred to a cancer care equity program (CCEP).

Emily Poles - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Testicular cancer ethnic disparities in the Waikato region, New Zealand.

Prashanth Hari Dass - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Real-world use of epoetin zeta compared to guidelines for chemotherapy-induced anemia.

Florian Scotte - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Epo-zeta

Physician attitudes to use of epoetin biosimilars in an established market.

Isabelle Laure Ray-Coquard - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Epo-zeta

The impact of insurance status on racial disparities in cancer outcomes for nonelderly adults: A population based analysis.

Hubert Pan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Reducing health disparities with the establishment of a new low-dose lung CT (LDCT) screening program.

Mary Pasquinelli - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Disparities in AIDS-related Kaposi sarcoma incidence and survival.

Firas El Chaer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

N/A

Variation from guidelines-based cancer treatment and disparity in patient outcomes throughout the United States.

Vincent W. Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of race on surgical management of pancreatic neuroendocrine tumors.

Jamii St. Julien - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient reported distress and survival after palliative radiotherapy.

Jacob Habboush - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient reported distress symptoms in patients undergoing palliative radiotherapy.

Megan Paige Single - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Assessing distress in patients with gastrointestinal tumors during radiotherapy.

Laeticia Hollant - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Anal cancer outcomes in patients treated with intensity modulated (IMRT) compared to 3-d conformal radiation therapy (3DCRT).

Gustavo Ferraris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Key drivers of physician decision-making in utilizing next generation sequencing results to guide cancer therapy.

Digant Gupta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Reducing VTE event rates in complex abdominal cancer surgery: A retrospective, single institute comparison of dextran vs heparin.

Richard Sleightholm - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Heparin

PET/CTs utility in identifying the primary and altering management in cancers of unknown primary.

Hannah Marie Cherniawsky - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Adverse event (AE) attribution in symptom intervention and cancer prevention trials.

Jennifer Le-Rademacher - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts